<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SCHEDULE 14A--INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant [X] Filed by a Party other than the
Registrant [_]
----------------
Check the appropriate box:
[_]Preliminary proxy statement
[_]Confidential, for the Use of the Commission Only (as permitted by Rule 14a-
6(e)(2))
[X]Definitive proxy statement
[_]Definitive additional materials
[_]Soliciting Material Pursuant to Rule 240.14a-11(c) or Rule 240.14a-12
----------------
Organogenesis Inc.
(Name of Registrant as Specified in Its Charter)
--------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X]No fee required.
[_]Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[_]Fee paid previously with preliminary materials.
[_]Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting Fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount previously paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing party:
(4) Date filed:
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
ORGANOGENESIS INC.
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
Date: Friday, May 14, 1999
Time: 10:00 a.m.
Place: The Westin Hotel
70 Third Avenue
Waltham, Massachusetts
Dear Stockholders:
You are cordially invited to attend our Annual Meeting of Stockholders and
to vote on the following proposals:
Item 1. Elect seven directors to serve for the ensuing year;
Item 2. Approve an amendment to our Restated Certificate of
Incorporation, as amended, increasing the number of authorized shares of
common stock from 40,000,000 to 80,000,000 shares;
Item 3. Approve amendments to our 1991 Employee Stock Purchase Plan to
extend the plan for an additional five years and to adjust the number of
shares authorized to be issued under each offering period to 30,000;
Item 4. Approve an amendment to our 1995 Stock Option Plan to increase
the number of shares of common stock available for issuance pursuant to
options granted from 2,929,688 to 5,000,000;
Item 5. Ratify the selection by the Board of Directors of
PricewaterhouseCoopers LLP as our independent accountants for the 1999
fiscal year; and
Item 6. Transact such other business as may properly come before the
meeting or any adjournment or adjournments thereof.
Stockholders of record at the close of business on March 19, 1999 will be
entitled to notice of, and to vote at, the meeting or any adjournment thereof.
The stock transfer books of the company will remain open for the purchase and
sale of our common stock.
By Order of the Board of Directors,
[SIGNATURE OF DONNA ABELLI-LOPOLITO APPEARS HERE]
Donna Abelli-Lopolito, Secretary
150 Dan Road
Canton, Massachusetts 02021
April 19, 1999
RETURN ENCLOSED PROXY CARD
YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND THIS MEETING,
PLEASE COMPLETE, SIGN AND DATE THE ENCLOSED PROXY AND PROMPTLY MAIL IT IN THE
ENCLOSED ENVELOPE IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES AT THE
MEETING. NO POSTAGE NEED BE AFFIXED IF THE PROXY IS MAILED IN THE UNITED
STATES.
<PAGE>
ORGANOGENESIS INC.
150 Dan Road
Canton, Massachusetts 02021
PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS
May 14, 1999
About This Proxy
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of Organogenesis Inc. for use at the 1999
Annual Meeting of Stockholders. This meeting will be held on Friday, May 14,
1999 at 10:00 a.m. at The Westin Hotel, 70 Third Avenue, Waltham,
Massachusetts. All proxies will be voted in accordance with the instructions
contained therein and, if no choice is specified, the proxies will be voted in
favor of the proposals set forth in the accompanying Notice of Annual Meeting.
You have the right to revoke your proxy and change your vote at any time prior
to its exercise at the meeting by giving written notice to that effect to the
Secretary of the company.
Voting Securities and Votes Required
The holders of a majority of the number of shares of common stock issued,
outstanding and entitled to vote on any matter shall constitute a quorum with
respect to that matter at the meeting. Shares of common stock present in
person or represented by proxy (including shares which abstain or do not vote
with respect to one or more of the matters presented for stockholder approval)
will be counted for purposes of determining whether a quorum is present.
The affirmative vote of the holders of a majority of the shares present, in
person or represented by proxy, and voting on the matter is required for
approval of each proposal, other than for the election of directors, which
requires a plurality of the votes cast at the meeting, and for the amendment
to the Company's Certificate, which requires the affirmative vote of the
holders of a majority of the outstanding shares of common stock entitled to
vote. With respect to the tabulation of votes, abstentions and broker non-
votes will not be counted, except for the proposals to approve the stock
plans, where abstentions will be counted as votes against the proposals, and
the proposal to amend the Company's Certificate, where abstentions and broker
non-votes will both be counted as votes against the proposal.
Record Date and Other Information
March 19, 1999 is the record date for the determination of stockholders
entitled to vote at the meeting. On this date, an aggregate of 30,454,300
shares of common stock (excluding treasury shares) were outstanding and
entitled to vote. Each share is entitled to one vote.
Our Annual Report for the year ended December 31, 1998 is being mailed to
stockholders concurrently with this Notice and Proxy Statement on or about
April 19, 1999.
On the following pages, we have provided information relating to the Board
of Directors, principal stockholders, and executive officers, as well as other
information required to be disclosed to stockholders, including a comparative
stock performance graph. Following this information are the proposals, items
one through six, as set forth in the Notice of Annual Meeting.
Information About the Board of Directors
The Board of Directors
The Board of Directors oversees the business and affairs of Organogenesis
Inc. and monitors the performance of management. In accordance with corporate
governance principles, the Board does not involve
<PAGE>
itself in day-to-day operations. The directors keep themselves informed
through discussions with the Chairman, other key executives, and our principal
external advisors (legal counsel and outside auditors), by reading reports and
other materials that we send them, and by participating in Board and committee
meetings.
During 1998, the Board of Directors held five meetings and four telephonic
meetings. Each incumbent director attended all (100%) of the Board of
Directors meetings that were held during his or her tenure and all committees
of the Board on which he or she served.
The Committees of the Board
The Audit Committee is comprised of Dr. Schrafl (chairman), Mr. Cresse and
Ms. Piret. The Audit Committee held one meeting during 1998. The
responsibilities of this committee are to: (1) make recommendations to the
Board of Directors regarding the engagement of independent accountants; (2)
review the arrangements for the scope of the independent audit and the results
of the audit and to report on the same to the Board of Directors; (3)
establish and monitor policy relative to non-audit services performed by the
independent accountants; and (4) assure that the accountants are in fact
independent.
The Compensation Committee is comprised of Mr. Cresse (chairman) and Dr.
Olsen. The Compensation Committee held two meetings during 1998, one
telephonic meeting and one written action in lieu of a meeting. This committee
provides recommendations to the Board of Directors as to all elements of
compensation arrangements with executive officers. It also administers the
1986 and 1995 Employee Stock Option Plans and the 1999 Nonqualified Stock
Option Plan.
The Executive Committee is comprised of Mr. Stein and Dr. Rovee. The
Executive Committee held one meeting during 1998. This committee provides
recommendations to the Board of Directors as to granting stock options to
employees, who are not officers or directors, under the 1986 and 1995 Employee
Stock Option Plans.
The Management Organization Committee is comprised of Mr. Novack (chairman),
Mr. Cresse, Dr. Olsen, Ms. Piret and Dr. Schrafl. The Management Organization
Committee met one time during 1998. This committee reviews and makes
recommendation on the company's management organization and the appointments
of other company employees referred to the committee.
The Nominating Committee is comprised of Dr. Schrafl (chairman), Mr. Cresse
and Mr. Stein. The Nominating Committee held two meetings during 1998. This
committee identifies and recommends candidates for nomination to the Board of
Directors. It does not consider nominees recommended by stockholders.
Compensation of Directors
Directors who are also officers of the company do not receive any
compensation for their services as directors. Directors who are not also
officers of the company receive $500 for each Board of Directors meeting
attended, $300 for each committee meeting attended and a retainer of $1,750
per quarter.
Under the 1994 Director Stock Option Plan approved by stockholders in 1994,
stock options to purchase 15,000 shares of common stock may be granted to non-
employee directors upon their initial election as a director. In addition, the
plan provides for the grant of options to purchase an additional 10,000 shares
to each eligible non-employee director on the second Wednesday of March in
each even numbered calendar year commencing in 1996. The plan provides that
the option price be at fair market value on the date of grant and vest in
equal annual installments over a five-year period beginning one year from the
date of grant. All options expire ten years from the date of grant.
2
<PAGE>
Information About Principal Stockholders
The following table sets forth certain information as of March 19, 1999 with
respect to the beneficial ownership of common stock by: (1) each person known
to own beneficially more than 5% of the outstanding shares of common stock;
(2) each director and nominee for director; (3) each of the executive officers
listed in the "Summary Compensation Table" contained on page seven of this
proxy; and (4) the directors and executive officers as a group:
<TABLE>
<CAPTION>
Shares of
Common Stock Percent of
Name and Address of Beneficially Common Stock
Beneficial Owner Owned (1) Outstanding
------------------- ------------ ------------
<S> <C> <C>
North American Management Corp. ................... 2,862,870(2) 9.4%
Ten Post Office Square
Boston, MA 02109
Herbert M. Stein................................... 2,081,597(3) 6.4%
71 Fairlee Road
Waban, MA 02168
David T. Rovee, Ph.D. ............................. 640,732(4) 2.1%
Richard S. Cresse.................................. 114,318(5) *
Albert Erani....................................... 1,362,508(6) 4.5%
Kenneth J. Novack.................................. 9,726(7) *
Bjorn R. Olsen, M.D., Ph.D. ....................... -- *
Marguerite A. Piret................................ 33,860(8) *
Anton E. Schrafl, Ph.D. ........................... 411,683(9) 1.3%
Robert J. Buehler, Ph.D. .......................... 88,068(10) *
Nancy L. Parenteau, Ph.D. ......................... 232,016(11) *
Michael L. Sabolinski, M.D. ....................... 303,766(12) *
All directors and officers as a group (13
persons).......................................... 5,362,268(13) 15.8%
</TABLE>
- --------
* Less than 1%.
(1) Except as otherwise specifically noted, the number of shares stated as
being owned beneficially includes shares believed to be held beneficially
by spouses, minor children and grandchildren. The inclusion of such shares
in this Proxy Statement, however, does not constitute an admission that
the named stockholders are direct or indirect beneficial owners of such
shares.
(2) The information reported is solely based on information provided by North
American Management Corp. Under common forms of discretionary account
agreements between investment adviser and client, an investment adviser is
vested with authority to dispose of shares. North American is an
investment adviser and is thus considered, under Securities and Exchange
Commission ("SEC") rules, to be a "beneficial owner." An investment
adviser need not have any pecuniary interest to be considered a beneficial
owner.
(3) Includes 1,938,139 shares of common stock that are subject to outstanding
options exercisable within the 60-day period following March 19, 1999;
107,666 shares held by H.M. Stein Associates and 35,792 shares owned. Does
not include 1,088,623 of the 1,196,289 shares of common stock held by H.M.
Stein Associates as to which Mr. Stein disclaims beneficial ownership.
(4) Includes 500 shares owned and 640,232 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(5) Includes 23,924 shares owned and 90,394 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(6) Based on a Form 4 filed as of January 11, 1999 with the SEC.
(7) Includes 5,976 shares owned and 3,750 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
3
<PAGE>
(8) Includes 1,476 shares owned and 32,384 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(9) Includes 306,641 shares owned and 105,042 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(10) Includes 20,997 shares owned and 67,071 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(11) Includes 4,883 shares owned and 227,133 shares of common stock that are
subject to outstanding options exercisable within the 60-day period
following March 19, 1999.
(12) Represents shares of common stock that are subject to outstanding options
exercisable within the 60-day period following March 19, 1999.
(13) Includes 1,362,508 shares held by Mr. Erani; 306,641 shares held by Dr.
Schrafl; 107,666 shares held by H.M. Stein Associates; 35,792 shares held
by Mr. Stein; 23,924 shares held by Mr. Cresse; 5,976 shares held by Mr.
Novack; 1,476 shares held by Ms. Piret; 500 shares held by Dr. Rovee;
20,997 shares held by Dr. Buehler; 4,883 shares held by Dr. Parenteau;
3,523 shares held by Mr. Alan Tuck (Chief Strategic Officer) and
3,488,382 shares of common stock subject to outstanding stock options
held by officers and directors that are exercisable within the 60-day
period following March 19, 1999.
Information About Executive Officers
General
The following table sets forth the name, age and current position of each
non-director executive officer and each such officer's business experience
during the past five years.
<TABLE>
<CAPTION>
Name and Age Position and Business Experience
------------ --------------------------------
<C> <S>
Donna Abelli-Lopolito......... Vice President, Finance and Administration and
Age 41 Chief Financial Officer, Treasurer and
Secretary since March 1996; Partner,
PricewaterhouseCoopers LLP prior to March 1996.
Robert J. Buehler, Ph.D. ..... Vice President, Operations since November 1995;
Age 51 Director, Process Development from August 1994
to November 1995; Director, Quality Assurance
from June 1993 to August 1994.
Nancy L. Parenteau, Ph.D. .... Senior Vice President, Research and Development
Age 45 and Chief Scientific Officer since August 1995;
Vice President, Cell and Tissue Science from
February 1994 to August 1995; Director, Cell
Biology Research prior to February 1994.
Michael L. Sabolinski, M.D. .. Senior Vice President, Medical and Regulatory
Age 43 Affairs since August 1995; Vice President,
Medical and Regulatory Affairs from February
1994 to August 1995; Director of Clinical and
Regulatory Affairs prior to February 1994.
Alan W. Tuck.................. Chief Strategic Officer since September 1997;
Age 50 at various times from August 1996 to June 1998:
Strategic Advisor to Dyax Corp, Executive Vice
President and Chief Strategic Officer Biocode
Inc., and Chief Strategic Officer ImmuLogic
Pharmaceutical Corporation; President & CEO T
Cell Sciences Inc. February 1992 to May 1996;
Vice President Marketing and Business
Development Biogen Inc. October 1987 to
November 1991. Director of Genzyme Transgenics
Corporation and Apogee Technology, Inc.
</TABLE>
4
<PAGE>
Compensation Committee Report on Executive Compensation
Overview: The Compensation Committee of the Board of Directors is comprised
of two independent non-employee directors and is responsible for developing
and making recommendations to the Board of Directors with respect to
compensation policies regarding executive officers. The committee also
recommends to the Board of Directors the base annual cash compensation and
annual cash bonuses to be paid to each executive officer. Additionally, the
committee grants options to executive officers.
The overall policy on compensation, as adopted by the committee, is to
provide competitive compensation to enable the company to attract and retain
qualified executive officers. The compensation of the executive officers is
structured and administered to promote the achievement of the company's
business goals and, thereby, to maximize corporate performance and stockholder
returns. The committee believes that, in addition to adequate base cash
compensation, it is important to have cash bonuses constitute a significant
portion of each executive officer's compensation package in order to tie an
individual's compensation level to individual and corporate performance. The
committee also believes it is important to have stock incentives constitute a
significant portion of each executive officer's compensation package to help
align long-term interests of executive officers with the interests of
stockholders.
Compensation of Executive Officers: Based upon the foregoing, the
compensation of executive officers consists of a mixture of cash base salary,
cash bonuses, fringe benefits and long-term common stock incentives. The
common stock incentives are provided through stock option plans. The company
also maintains a contributory 401(k) program in which executive officers may
participate. The maximum contribution that may be paid in any one year by the
company under the 401(k) program on behalf of any one employee is $900. In
determining the total amount and mixture of the compensation package for each
executive officer, the committee, at least once a year, takes into
consideration numerous factors such as: (1) compensation of executive officers
performing similar functions at comparable and competitive companies; (2)
individual performance of each executive officer, including contribution to
the company's goals; and (3) the company's short-term and long-term needs and
goals, including attracting and retaining key management personnel. As a
result of this evaluation, the committee recommends to the Board for approval
for each executive officer appropriate changes in existing base salary
effective March 1 of each year and an annual cash bonus payable after the end
of the calendar year.
The stock option program is the company's major long-term incentive plan to
compensate executive officers. The objectives of this program are to align the
executive officers' and stockholders' long-term interests by creating a strong
and direct link between executive pay and stockholder return and to enable the
executive officers to develop and maintain significant long-term stock
ownership in the company's common stock. Stock options generally are granted
at an option price equal to the fair market value of the common stock on the
date of grant, have ten year terms, and vest ratably over five years. The
amount of shares granted increases as a function of higher salary and
position. The committee granted stock options to seven executive officers in
1998 to make their compensation package fully competitive with other companies
in the industry, as well as with a broader group of companies of comparable
size and complexity.
Compensation of Chief Executive Officer: Mr. Stein, Chief Executive Officer,
is eligible to participate in the same executive compensation programs
available to other executive officers. The committee has set Mr. Stein's
annual compensation at a level it believes necessary to retain Mr. Stein in
his executive position and to be comparable with other companies in the
industry. Accordingly, in March 1998, Mr. Stein's annual base salary was
increased to $340,000 from $316,440 the year before.
In addition, the committee awarded Mr. Stein a cash bonus of $145,000 and
stock options to acquire an aggregate of 187,500 shares of common stock at an
exercise price equal to the fair market value on the date of grant. The stock
options vest ratably over five years following the date of grant and are
subject to Mr. Stein's continued employment with the company. In May 1997, the
Board of Directors voted to amend an option granted to Mr. Stein in 1987. The
option, which was due to expire in May 1997, was extended for an additional
five years. The terms of this fully vested option are to purchase 732,423
shares of common stock at an exercise price
5
<PAGE>
of $3.07. The bonus and stock options awarded reflect achievement of and
progress towards the company's and Mr. Stein's principal 1998 and future goals
and objectives.
Compliance with Internal Revenue Code Section 162(m): Section 162(m) of the
Internal Revenue Code of 1986, as amended (the "Code"), enacted in 1993,
generally disallows tax deductions to publicly traded corporations for
compensation over $1 million paid to a corporation's Chief Executive Officer
and any of its four other most highly compensated executive officers.
Qualifying performance-based compensation will not be subject to this
disallowance if certain requirements are met. The company intends to structure
its compensation arrangements in a manner that will avoid disallowances under
Section 162(m).
Compensation Committee:
Richard S. Cresse, Chairperson
Bjorn R. Olsen, M.D. Ph.D.
6
<PAGE>
Summary Compensation Table
The following table sets forth information for each of the last three fiscal
years relating to the compensation of the Chairman and Chief Executive Officer
and four other most highly compensated executive officers who received cash
salary and bonus in excess of $100,000 during 1998 (collectively, the "Named
Executive Officers"):
<TABLE>
<CAPTION>
Long-Term
Compensation
Securities
Annual Compensation Underlying
Name and Principal ----------------------- Stock All Other
Position Year Salary($) Bonus($) Options(#) Compensation($)
------------------ ---- --------- -------- ------------ ---------------
<S> <C> <C> <C> <C> <C>
Herbert M. Stein......... 1998 $351,899 $145,000 187,500 $19,594(1)
Chairman and Chief 1997 315,358 95,000 263,672 19,594(1)
Executive Officer 1996 291,969 95,000 263,672 19,594(1)
David T. Rovee, Ph.D. ... 1998 292,558 95,000 125,000 10,542(2)
President, Chief 1997 263,492 60,000 175,781 900(3)
Operating Officer 1996 243,346 60,000 175,781 900(3)
Michael L. Sabolinski, 1998 185,000 60,000 62,500 900(3)
M.D. ................... 1997 168,077 35,000 68,359 900(3)
Senior Vice President, 1996 158,154 35,000 87,891 900(3)
Medical Affairs and
Regulatory
Nancy L. Parenteau, 1998 184,039 65,000 68,750 900(3)
Ph.D. .................. 1997 162,116 40,000 78,125 900(3)
Senior Vice President, 1996 145,385 30,000 87,891 900(3)
Research and Development
and Chief Scientific
Officer
Robert J. Buehler, 1998 148,104 40,000 37,500 900(3)
Ph.D. .................. 1997 126,731 40,000 48,828 900(3)
Vice President, 1996 111,789 15,000 19,531 900(3)
Operations
</TABLE>
- --------
(1) Amounts shown are insurance premiums paid by the company for a life
insurance policy on Mr. Stein of which the company is not a beneficiary
and $10,000 paid for personal financial consulting services.
(2) Amount shown includes $9,642 for relocation expenses paid in accordance
with Dr. Rovee's employment agreement and $900 contributed by the company
pursuant to its 401(k) Plan.
(3) Reflects amounts contributed by the company pursuant to its 401(k) Plan.
7
<PAGE>
Option Grants in Last Fiscal Year
The following table sets forth information regarding options granted during
the year ended December 31, 1998 to the Named Executive Officers:
<TABLE>
<CAPTION>
Individual Grants
-------------------------------
Number Percent of
Of Total Potential Realized Value
Securities Options at Assumed Annual Rates
Underlying Granted to of Stock Price Appreciation
Options Employees Exercise Grant Date for Option Term(2)
Granted In Fiscal Price(1) Expiration Value ----------------------------
Name (#) Year ($/Share) Date At 0% At 5% At 10%
- ---- ---------- ---------- --------- ---------- ---------- ------------- --------------
<S> <C> <C> <C> <C> <C> <C> <C>
Herbert M. Stein........ 187,500 19.95% $24.80 3/17/08 $-- $ 2,924,360 $ 7,410,902
David T. Rovee, Ph.D.... 125,000 13.30 24.80 3/17/08 -- 1,949,573 4,940,602
Michael L. Sabolinski,
M.D. .................. 62,500 6.65 24.80 3/17/08 -- 974,787 2,470,301
Nancy L. Parenteau,
Ph.D................... 68,750 7.31 24.80 3/17/08 -- 1,072,265 2,717,331
Robert J. Buehler,
Ph.D................... 37,500 3.99 24.80 3/17/08 -- 584,872 1,482,180
</TABLE>
- --------
(1) All options were granted at an exercise price equal to the fair market
value of common stock on the date of grant. Options are exercisable in
five equal annual installments of 20% each year commencing one year from
the date of grant. In addition, the options vest fully in the event of a
change in control. See "Compensation Arrangements" on the next page.
(2) Amounts shown under these columns are the results of calculations of the
5% and 10% rates required by the SEC and are not intended to forecast
future appreciation of the stock price. The table does not take into
account any appreciation in the price of the common stock to date.
The following table sets forth certain information regarding options held as
of December 31, 1998 by the Named Executive Officers.
Aggregated Option Exercises in Last Fiscal Year
and Fiscal Year-End Option Values
<TABLE>
<CAPTION>
Number of Securities
Underlying Unexercised Value of Unexercised
Options at In-the-money Options at
Shares Fiscal Year-End(1) Fiscal Year-End(1)(2)
Acquired on Value ------------------------- -------------------------
Name Exercise(#) Realized($) Exercisable Unexercisable Exercisable Unexercisable
- ---- ----------- ----------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Herbert M. Stein........ -- $ -- 1,736,575 644,532 $11,624,419 $963,283
David T. Rovee, Ph.D. .. -- -- 505,857 429,690 2,897,472 642,199
Michael L. Sabolinski,
M.D. .................. -- -- 235,600 208,985 1,307,365 374,528
Nancy L. Parenteau,
Ph.D. ................. -- -- 160,647 218,166 838,355 351,314
Robert J. Buehler,
Ph.D. ................. -- -- 45,899 97,802 147,967 50,814
</TABLE>
- --------
(1) Options granted under the 1986 and 1995 Stock Option Plans become
exercisable in five equal annual installments of 20% each year commencing
one year from the date of grant.
(2) The value of unexercised in-the-money options represents the difference
between the closing price of the company's common stock on the American
Stock Exchange on December 31, 1998 and the option exercise price.
Compensation Arrangements
The company has a Severance Benefits Plan for all of the executive officers,
including Mr. Stein and Dr. Rovee, that provides for certain benefit payments
in the event that an officer's employment is terminated involuntarily
following a change in control of the company. As defined in the plan, a change
in control will
8
<PAGE>
occur: (1) in the event that any person acquires 30% or more of the combined
voting power of the company's then outstanding securities; (2) if a majority
of the Board of Directors changes, unless the change was approved by a vote of
at least a majority of the Board of Directors prior to such change; (3) in the
event that the stockholders approve a merger or consolidation of the company,
other than a merger or consolidation that would result in the voting
securities outstanding immediately prior thereto continuing to represent more
than 50% of the combined voting power of the voting securities of the company
or the surviving entity outstanding immediately after such merger or
consolidation, or a merger or consolidation effected to implement a
recapitalization of the company in which no person acquires more than 30% of
the combined voting power of the company's then outstanding securities; or (4)
in the event that the stockholders of the company approve a plan of complete
liquidation or the sale of all or substantially all of the company's assets.
All stock options held by employees, including executive officers, and
directors fully vest upon a change in control, as defined above.
1999 Nonqualified Stock Option Plan
Introduction: On March 19, 1999, the Board of Directors adopted the 1999
Nonqualified Stock Option Plan (the "1999 Plan") providing for the issuance of
up to 1,000,000 shares of common stock (subject to adjustment for any
dividend, stock split or other relevant changes in capitalization). The Board
of Directors' primary reason for adopting the 1999 Plan was to enhance the
company's ability to retain and motivate key qualified persons who are
officers, directors, and consultants. The market value of the total number of
shares that may be issued under the 1999 Plan is $13,125,000, based on the
closing price of the common stock on the American Stock Exchange on March 19,
1999.
Summary of the 1999 Plan: Under the 1999 Plan, the Compensation Committee of
the Board of Directors may grant non-qualified stock options to officers,
directors, and consultants. The committee selects the individuals to whom
options are granted and determines: (1) the number of shares of common stock
covered by the option; (2) when the option becomes exercisable; (3) the
duration of the option, which may not exceed ten years; and (4) the vesting
period, which, for officers, will generally occur ratably over a five-year
period beginning one year from the date of grant. All stock options held under
this plan fully vest upon a change in control, as defined above in the
previous section.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
directors, officers, and persons who own more than 10% of the company's common
stock to file initial reports of ownership and reports of changes in ownership
with the SEC and the American Stock Exchange. Such persons are required by SEC
regulation to furnish the company with copies of all Section 16(a) forms they
file.
Based solely on a review of the copies of such forms received by us with
respect to 1998, or written representations from certain reporting person, we
believe that, during the preceding year, directors, officers and persons who
own more than 10% of the company's common stock have complied with all filing
requirements, except that one Form 3 report was not filed on a timely basis
covering options to acquire common stock by Alan W. Tuck, an officer.
Certain Transactions
In 1995, the company's wholly owned subsidiary, ECM Pharma Inc., licensed
from Harvard University a compound that has the potential to regulate the
breakdown of extracellular matrix and to modify tissue remodeling. ECM Pharma
also entered into a research collaboration with Harvard Medical School, under
the direction of Dr. Olsen, related to the discovery of extracellular matrix-
related therapeutics. We expended approximately $217,691 and $38,082 during
1997 and 1998, respectively, to fund the research collaboration. Dr. Olsen is
a member of the Board of Directors.
9
<PAGE>
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. are legal counsel to the
company. Mr. Novack, who joined the Board of Directors in March 1998, is Of
Counsel to this firm.
As of March 31, 1999, we raised $20,000,000 through the private placement of
7%, five-year convertible debentures and 400,000 warrants to purchase common
stock. The debentures are convertible at a fixed price of $15.00 per share and
mature on March 29, 2004. The warrants grant the right to purchase one share
of common stock at the exercise price of $22.50 for each $50.00 in face value
of the convertible notes at any time before March 30, 2004. Mr. Erani, a
member of the Board of Directors and principal stockholder, purchased
$2,500,000 of the convertible notes and North American Management Corporation,
a principal stockholder, purchased $1,250,000 of the convertible notes.
Scientific Advisory Board
We have a Scientific Advisory Board comprised of five physicians, professors
and scientists in various fields of medicine and science. The SAB meets from
time to time to advise and consult with management and scientific staff.
Members of the SAB receive a $1,000 fee for each meeting attended and are
reimbursed for expenses in attending meetings. Non-statutory stock options
have been granted to members of the SAB. As of March 19, 1999, members of the
SAB held options, in connection with their service as SAB members, to purchase
an aggregate of 4,883 shares of common stock at an average exercise price of
$8.32 per share under the 1986 Stock Option Plan.
Comparative Stock Performance Graph
The graph below compares the cumulative total stockholder return on the
company's common stock against the cumulative total return of the Standard &
Poor's 500 Stock Index and the AMEX Biotechnology Index during the five years
ending December 31, 1998. The graph and table assume $100 was invested on
December 31, 1993 in the company's common stock and in each of the foregoing
indices.
[GRAPH APPEARS HERE]
<TABLE>
<CAPTION>
1993 1994 1995 1996 1997 1998
------ ------ ------ ------ ------ ------
<S> <C> <C> <C> <C> <C> <C>
Organogenesis Inc 100.00 220.83 255.21 315.97 583.22 298.39
S&P 500 Index 100.00 101.36 139.33 171.24 228.35 293.60
AMEX Biotechnology Index 100.00 70.88 115.54 124.63 140.28 159.90
</TABLE>
10
<PAGE>
ITEM NO. 1
ELECTION OF DIRECTORS
Unless otherwise instructed, the persons named in the enclosed proxy will
vote to elect as directors the seven nominees named below. Each director will
be elected to hold office until the next annual meeting of stockholders or
until his or her successor is elected and qualified. If a nominee becomes
unavailable, the person acting under the proxy may vote the proxy for the
election of a substitute. We do not presently contemplate that any of the
nominees will be unavailable.
The following table sets forth the name and age of each nominee and the
positions and offices held by him or her, his or her principal occupation and
business experience during the past five years, when he or she first became a
director of the company and the names of other publicly held companies of
which he or she serves as a director:
<TABLE>
<CAPTION>
Principal Occupation, First
Business Experience Became a
Name and Age and Directorships Director
------------ --------------------- --------
<C> <S> <C>
Richard S. Cresse............. Consultant; Corporate Vice 1986
Age 71 President, Arthur D. Little, Inc.
from 1988 to 1997.
Albert Erani.................. Founder and Principal of A&E Stores, 1998
Age 58 Inc.; Principal of Vanlex Stores,
Inc.
Bjorn R. Olsen, M.D., Ph.D. .. Professor of Oral Biology and 1994
Age 58 Chairman, Harvard-Forsyth Department
of Oral Biology, Forsyth Dental
Center, Harvard School of Dental
Medicine since 1998. Hersey
Professor of Cell Biology,
Department of Cell Biology, Harvard
Medical School prior to 1998.
Marguerite A. Piret........... President of Newbury, Piret & 1995
Age 51 Company, Inc., an investment banking
company, since 1981; Trustee of the
Pioneer Mutual Funds.
David T. Rovee, Ph.D. ........ President and Chief Operating 1994
Age 59 Officer of Organogenesis Inc. since
February 1994; Vice President of
Research and Development from
November 1991 to February 1994;
employed by Johnson & Johnson for
the prior 25 years; Director of
Specialized Health Products
International, Inc.
Anton E. Schrafl, Ph.D. ...... Deputy Chairman of "Holderbank" 1987
Age 67 Financiere Glaris Ltd., a Swiss
manufacturer of cement, since July
1984; Director of Apogee Technology,
Inc.
Herbert M. Stein.............. Chairman of the Board of Directors 1986
Age 70 of Organogenesis Inc. since February
1991; Chief Executive Officer since
January 1987; Director of Ekco
Group, Inc. and Apogee Technology,
Inc.
</TABLE>
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ELECTING THESE SEVEN NOMINEES
11
<PAGE>
ITEM NO. 2
PROPOSAL TO AMEND THE RESTATED CERTIFICATE OF INCORPORATION
On March 19, 1999, the Board of Directors voted to amend the Restated
Certificate of Incorporation, subject to stockholder approval, to increase the
number of authorized shares of common stock from 40,000,000 to 80,000,000
shares. Stockholders are being asked to approve this amendment at the Annual
Meeting.
Authorized common stock currently consists of 40,000,000 shares, $.01 par
value per share, of which 30,454,300 shares (excluding 40,000 treasury shares)
were outstanding as of March 19, 1999. Approximately 6,362,662 shares were
duly authorized and reserved for issuance pursuant to stock option plans;
320,335 shares were duly authorized and reserved for issuance pursuant to a
stock purchase plan; and 663,712 shares were duly authorized and reserved for
issuance pursuant to outstanding warrants and Series C convertible preferred
stock outstanding. The Board of Directors believes that the authorization of
additional shares of common stock is desirable to provide shares for issuance
in connection with possible future stock dividends, future financings, joint
ventures, acquisitions or other general corporate purposes. However, there is
no existing plan, understanding or agreement for the issuance of any shares of
common stock with the exception of the shares of common stock available for
issuance described above. If the amendment is adopted by the stockholders, the
Board of Directors will have authority to issue shares of common stock without
the necessity of further stockholder action. Holders of common stock have no
preemptive rights with respect to any shares that may be issued in the future.
The Board of Directors Believes that Approval of the Amendment to the
Restated Certificate of Incorporation is in the Best Interests of the Company
and its Stockholders and Recommends a Vote "FOR" this Proposal.
12
<PAGE>
ITEM NO. 3
PROPOSAL TO AMEND THE 1991 EMPLOYEE STOCK PURCHASE PLAN
Introduction
The stockholders approved the 1991 Employee Stock Purchase Plan, which was
subsequently amended at the 1993 Annual Meeting of Stockholders. As amended,
the plan currently provides for sixteen semi-annual offerings of 12,500 shares
each. To date 45,878 shares have been issued under the plan. On March 19,
1999, the Board of Directors voted to amend the plan, subject to stockholder
approval, to: (1) extend the plan for five additional years; (2) authorize ten
additional semi-annual offerings of 30,000 shares each; and (3) amend,
accordingly, the offering commencement and termination dates. If not amended,
the plan will terminate on December 31, 1999. The Board of Directors believes
the amendments are necessary to continue to provide an incentive to current
employees and attract new employees. Stockholders are being asked to approve
this amendment at the Annual Meeting.
Administration and Eligibility
The Compensation Committee of the Board of Directors administers the plan
and is authorized to decide questions of eligibility and to make rules and
regulations for the administration and interpretation of the plan. With
certain exceptions, all employees, including officers, employed for at least
six months on the applicable offering commencement date are eligible to
participate in the plan. We currently have approximately 168 eligible
employees. Non-employee directors are not eligible to purchase shares under
the plan.
Offerings; Number and Purchase Price of Shares
The plan, as amended, will consist of semi-annual offerings of 30,000 shares
each. The number of shares available for an offering may be increased, at the
election of the Compensation Committee, by the number of shares, if any, that
were made available, but not purchased, during an earlier offering.
During each offering, the maximum number of shares that may be purchased by
a participating employee is determined on the first day of the offering period
under a formula whereby 85% of the market value of a share of common stock on
the first day of the offering period is divided into an amount equal to the
percentage of the employee's monetary compensation that he or she has elected
to have withheld during the offering period. An employee may elect to have up
to 5% deducted from his or her regular salary (as adjusted) for this purpose.
The price at which the employee's option is exercised is the lower of (1) 85%
of the closing price of the common stock on the American Stock Exchange on the
day that the offering commenced or (2) 85% of the closing price on the day
that the offering terminates.
Offerings under the plan commence on January 1 and July 1 and terminate,
respectively, on June 30 and December 31. The final offering under the plan,
as amended, will terminate on December 31, 2004. The fair market value of the
common stock available under the plan was $4,204,397 as of March 19, 1999.
Federal Income Tax Consequences
The plan is intended to qualify as an "employee stock purchase plan" as
defined in Section 423 of the tax code. The tax code provides that the
employee will not realize any federal tax consequences when such employee
joins the plan, or when an offering ends and such employee receives shares of
the company's common stock. The employee must, however, recognize income or
loss on the difference, if any, between the price at which he or she sells the
shares and the price he or she paid for them. If the employee has owned the
shares for more than one year, disposes of them at least two years after the
date an offering commenced, and the market price of the shares on the date of
sale is equal to or less than the purchase price under the plan, he or she
will recognize a
13
<PAGE>
long-term capital loss in the amount equal to the price paid over the sale
price. If the employee has owned the shares for more than one year, more than
two years has elapsed from the date the offering commenced, and the market
price of the shares on the date of sale is higher than the purchase price
under the plan, the employee must recognize ordinary income in an amount equal
to the lesser of (a) the fair market value of the shares on the day the
offering commenced over the price paid, or (b) the excess of the amount
actually received for the shares over the purchase price. Any further gain
will be treated as long-term capital gain.
If the employee sells the shares prior to holding them for more than one
year or prior to two years from the date the offering commenced, he or she
must recognize ordinary income in the amount of the difference between the
price he or she paid for the shares and the market price of the shares on the
date of purchase. The company will receive an expense deduction for the same
amount, subject to the limitations of Section 162(m) of the tax code. The
employee will also recognize a capital gain or loss on the difference between
the sale price and the market price on the date of purchase. The company will
not be entitled to a tax deduction upon either the purchase or sale of shares
under the plan if the holding period requirements set forth above are met. The
plan is not qualified under Section 401(a) of the Code.
Amendment of the Purchase Plan
The Board of Directors may, at any time, terminate or amend the plan.
However, no such termination can affect options previously granted, nor may an
amendment make any change in any option theretofore granted that would
adversely affect the rights of any participant. Additionally, an amendment may
not be made without the approval of the stockholders within twelve months of
such amendment, if such amendment would (1) materially increase the benefits
accruing to the participants, (2) materially increase the number of shares
that may be issued under the plan, or (3) materially modify the requirements
as to eligibility for participation under the plan.
Because participation in the plan is voluntary, we cannot now determine the
number of shares of common stock to be purchased by any particular executive
officer, by all current executive officers as a group or by employees (other
than executive officers) as a group. For additional information regarding
ownership of the company's common stock by executive officers, see "Principal
Stockholders" on page three of this proxy.
The Board of Directors Believes that Approval of the Amendments to the
Employee Stock Purchase Plan is in the Best Interests of the Company and its
Stockholders and Recommends a Vote "FOR" this Proposal.
14
<PAGE>
ITEM NO. 4
PROPOSAL TO AMEND THE 1995 STOCK OPTION PLAN
Introduction
The 1995 Stock Option Plan (the "1995 Plan") was first approved by
shareholders at the 1995 Annual Meeting of Stockholders. The 1995 Plan was
intended to replace the 1986 Stock Option Plan (the "1986 Plan"), which was
due to expire. The Board of Directors believes that the continued growth and
success of the company depends, in a large part, upon its ability to attract,
retain and motivate employees. Accordingly, on March 19, 1999, the Board of
Directors voted to amend the 1995 Plan, subject to stockholder approval, to
increase the number of shares of common stock specifically reserved for
issuance under the 1995 Plan by 2,070,312 shares, from 2,929,688 shares to
5,000,000 shares. The increase of 2,070,312 shares equals approximately 6.8%
of the shares of common stock outstanding on March 19, 1999. Stockholders are
being asked to approve this amendment at the Annual Meeting.
Administration and Eligibility
The 1995 Plan is administered by the Executive Committee of the Board of
Directors and, for purposes of grants to officers and directors subject to
Section 16 of the Securities Exchange Act of 1934, by the Compensation
Committee of the Board of Directors. Both non-statutory stock options and
incentive stock options intended to qualify under Section 422 of the tax code
may be granted under the 1995 Plan. All officers and employees are eligible to
receive incentive stock options under the 1995 Plan. All officers, directors,
employees and non-employee consultants, including members of the Scientific
Advisory Board, are eligible to receive non-statutory options under the 1995
Plan.
The Executive and Compensation Committees select the individuals to whom
options are granted and determine: (1) the type of option to be granted; (2)
the number of shares of common stock covered by the option; (3) when the
option becomes exercisable; and (4) the duration of the option which, in the
case of incentive stock options, may not exceed ten years. Vesting generally
occurs ratably over a five-year period beginning one year from the date of
grant. No one person may be issued options to purchase more than 500,000
shares of common stock in any one calendar year. Stock options granted under
the 1995 Plan may not be granted at an exercise price less than 100% of the
fair market value of the common stock on the date of grant (or 110% of fair
market value in the case of incentive stock options granted to employees
holding 10% or more of voting stock). The aggregate fair market value
(determined at the time of grant) of shares issuable pursuant to incentive
stock options which first become exercisable in any calendar year by an
employee may not exceed $100,000.
Federal Income Tax Consequences
The following is a summary of the federal income tax treatment of incentive
stock options and non-statutory stock options. The tax consequences recognized
by an optionee may vary; therefore, an optionee should consult his or her tax
advisor for advice concerning any specific transaction.
Incentive Stock Options: No taxable income will be recognized by an optionee
upon the grant or exercise of an incentive stock option granted under the 1985
Plan, and no corresponding expense deduction will be available to the company.
Generally, if an optionee holds shares acquired upon the exercise of incentive
stock options until the later of (1) two years from the grant of the option
and (2) one year from the date of transfer of the purchased shares to him or
her (the "Statutory Holding Period"), any gain recognized by the optionee of a
sale of such shares will be treated as capital gain. The gain recognized upon
the sale of the stock is the difference between the option price and the sale
price of the stock. The net federal income tax effect on the holder of
incentive stock options is to defer, until the stock is sold, taxation of any
increase in the stock's value from the time of grant to the time of exercise.
15
<PAGE>
If the optionee sells the shares prior to the expiration of the Statutory
Holding Period (a "disqualifying disposition"), he or she will realize taxable
income at ordinary income tax rates in an amount equal to the lesser of (1)
the fair market value of the shares on the date of exercise less the option
price, or (2) the amount realized on the disposition of the stock less the
option price, and the company will receive a corresponding business expense
deduction. However, special rules may apply to an optionee who is an officer
or a director. The amount by which the proceeds of sale exceeds the fair
market value of the shares on the date of exercise will be treated as long-
term capital gain if the shares are held for more than one year prior to the
sale and a short-term capital gain if the shares are held for a shorter
period. In the case of a sale where a loss, if sustained, would have been
recognized, the amount of the optionee's income, and the amount of the
company's corresponding expense deduction, will not exceed the difference
between the sale price and the adjusted basis of the shares.
Non-Statutory Stock Options: No taxable income is recognized by the optionee
upon the grant of a non-statutory qualified stock option. The optionee must
recognize as ordinary income in the year in which the option is exercised the
amount by which the fair market value of the purchased shares on the date of
exercise exceeds the option price. However, special rules may apply to options
held by directors and officers. The company will be entitled to a business
expense deduction equal to the amount of ordinary income recognized by the
optionee. Any additional gain or any loss recognized upon the subsequent
disposition of the purchased shares will be a capital gain or loss, and will
be a long-term gain or loss if the shares are held for more than one year.
Change in Control of the Company
In the event of a change of control (as defined below), all grants
outstanding as of the date such change in control occurs shall become
exercisable in full, whether or not exercisable in accordance with their
terms. A change in control will occur or be deemed to have occurred only if
any of the following events occur: (1) any "person," as such term is used in
Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act") (other than the company, any trustee or other fiduciary
holding securities under an employee benefit plan, or any corporation owned
directly or indirectly by stockholders in substantially the same proportion as
their ownership of stock), is or becomes the "beneficial owner" (as defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, of securities
representing 30% or more of the combined voting power of the then outstanding
securities; (2) individuals who, as of the date this plan is adopted,
constitute the Board of Directors (as of the date thereof, the "Incumbent
Board") cease for any reason to constitute at least a majority of the Board,
provided that any person becoming a director subsequent to the date thereof
whose election, or nomination for election by stockholders, was approved by a
vote of at least a majority of the directors then comprising the Incumbent
Board (other than an election or nomination of an individual whose initial
assumption of office is in connection with an actual or threatened election
contest relating to the election of the directors, as such terms are used in
Rule 14a-11 of Regulation 14A under the Exchange Act) will be, for purposes of
this plan, considered as though such person were a member of the Incumbent
Board; (3) stockholders approve a merger or consolidation with any other
corporation, other than (A) a merger or consolidation that would result in the
voting securities outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity) more than 30% of the combined voting power
of the voting securities of the company or such surviving entity outstanding
immediately after such merger or consolidation or (B) a merger or
consolidation effected to implement a recapitalization (or similar
transaction) in which no "person" (as hereinabove defined) acquires more than
30% of the combined voting power of the then outstanding securities; or (4)
the stockholders approve a plan of complete liquidation or an agreement for
the sale or disposition of all or substantially all of the company's assets.
Section 162(m)
Under Section 162(m) of the tax code, the deductibility of certain
compensation paid to the chief executive officer and each of the four other
most highly compensated executives of publicly held companies is limited to
$1,000,000. Compensation for this purpose generally includes any items of
compensation expense described above in connection with incentive awards under
the 1995 Plan. However, certain types of compensation are exempted from this
limit, including compensation that qualifies as "performance-based
compensation." Under
16
<PAGE>
Section 162(m), any compensation expense resulting from the exercise of
options under the 1995 Plan with exercise prices equal to (or greater than)
the fair market value of the common stock on the date of grant should qualify
as "performance-based compensation" exempted from the limit of Section 162(m).
However, compensation expense in connection with any other incentive awards
under the 1995 Plan will be subject to this limit.
Outstanding Options
As related to the 1995 Plan as of March 19, 1999:
. Options outstanding were held by 192 officers, employees and consultants
for the purchase of a total of 2,626,186 shares of common stock at
exercise prices of $8.32 to $31.00 per share;
. 142,265 shares of common stock remained available for future grants;
. The average exercise price for options outstanding was $14.52 per share;
and
. The expiration dates of options outstanding ranged from March 13, 2006
to March 15, 2009.
The following table sets forth, as to the executive officers named in the
compensation table on page seven and as to all executive officers as a group,
the number of shares of common stock covered by options granted between
January 1, 1996 and March 19, 1999 and the weighted average per share option
price thereof. No options were exercised by these officers during the relevant
period.
<TABLE>
<CAPTION>
Granted January 1, 1996 to
March 19, 1999
------------------------------
Number of
Shares Weighted
Covered by Average Per
Options Share Option
Name Granted Price
---- -------------- --------------
<S> <C> <C>
Herbert M. Stein................................ 714,846 $ 13.82
David T. Rovee, Ph.D............................ 476,563 10.75
Michael L. Sabolinski, M.D...................... 218,751 10.69
Nancy L. Parenteau, Ph.D........................ 234,767 11.10
Robert J. Buehler, Ph.D. ....................... 105,859 15.63
All officers as a group (7 persons)............. 1,938,287 13.71
</TABLE>
The Board of Directors Believes that Approval of the Amendments to the 1995
Stock Incentive Plan is in the Best Interests of the Company and its
Stockholders and Recommends a Vote "FOR" this Proposal.
17
<PAGE>
ITEM NO. 5
PROPOSAL TO RATIFY THE SELECTION OF INDEPENDENT ACCOUNTANTS
The Board of Directors has selected PricewaterhouseCoopers LLP as
independent accountants for the 1999 fiscal year. PricewaterhouseCoopers LLP
has served as independent accountants since 1986. Representatives of
PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting.
They will have the opportunity to make a statement if they so desire and will
also be available to respond to appropriate questions from stockholders.
Stockholders are being asked to ratify this selection at the Annual Meeting.
The Board of Directors Recommends a Vote "FOR" Ratification of the Selection
of the Independent Accountants
ITEM NO. 6
OTHER MATTERS
We do not know of any other matters that may come before the meeting.
However, if any other matters are properly presented to the Annual Meeting, it
is the intention of the persons named in the accompanying proxy to vote, or
otherwise act, in accordance with their judgment on such matters.
The expenses connected with soliciting proxies will be borne by the company.
In addition to solicitations by mail, directors, officers and regular
employees, without additional remuneration, may solicit proxies by telephone,
telegraph and personal interviews. We will pay a fee of approximately $7,000
to Georgeson & Company Inc. to assist with the solicitation of proxies.
Brokers, custodians and fiduciaries will be requested to forward proxy
soliciting material to the owners of stock held in their names, and will be
reimbursed for out-of-pocket expenses in connection with the distribution of
proxy materials.
Deadline for Submission of Stockholders Proposals
In order to be considered for addition to the agenda for the Annual Meeting
of Stockholders in the year 2000 and to be included in the Proxy Statement and
form of proxy, stockholders' proposals must be received by the company no
later than December 3, 1999. In order to be considered for presentation at the
Annual Meeting of Stockholders in the year 2000, although not included in the
proxy statement, a stockholder proposal must comply with the requirements of
the Company's Restated By-Laws and be received by the Company no later than
February 28, 2000 and no earlier than January 28, 2000. Stockholder proposals
should be delivered in writing to the Secretary, Organogenesis Inc., 150 Dan
Road, Canton, Massachusetts 02021. A copy of the Company's Restated By-Laws
may be obtained from the Company upon written request to the Secretary.
By Order of the Board of Directors,
[SIGNATURE OF DONNA ABELLI-LOPOLITO APPEARS HERE]
Donna Abelli-Lopolito, Secretary
Canton, Massachusetts
April 19, 1999
THE BOARD OF DIRECTORS HOPES THAT STOCKHOLDERS WILL ATTEND THE ANNUAL
MEETING. WHETHER OR NOT YOU PLAN TO ATTEND, YOU ARE URGED TO COMPLETE, SIGN,
DATE AND RETURN THE ENCLOSED PROXY IN THE ACCOMPANYING ENVELOPE. PROMPT
RESPONSE WILL GREATLY FACILITATE ARRANGEMENTS FOR THE ANNUAL MEETING AND YOUR
COOPERATION IS APPRECIATED. STOCKHOLDERS WHO ATTEND THE ANNUAL MEETING MAY
VOTE THEIR STOCK PERSONALLY EVEN THOUGH THEY HAVE SENT IN THEIR PROXIES.
18
<PAGE>
1999 Annual Shareholder Meeting
Westin Hotel, Waltham
Friday, May 14, 1999
Organogenesis Inc. will host its 1999 Annual Shareholder Meeting
at the Westin Hotel in Waltham, MA on Friday, May 14, 1999.
Shareholders Please Note:
Registration will open at 9:00 AM
Meeting will start promptly at 10:00 AM
Directions to the Annual Meeting Site:
From I-95 (Route 128)--Exit 27A, Totten Pond Road.
From I-95 South--Exit 27A, cross overpass to stoplight.
Take right onto Third Avenue.
From I-95 North--Exit 27A, keep right at fork in the ramp.
Make hairpin turn onto Third Avenue.
From Logan Airport--Follow signs to exit airport. After exiting airport,
follow signs to Sumner Tunnel. After exiting tunnel, take I-93 South to I-90
West (Mass. Turnpike) to I-95 North (follow directions above).
Hotel entrance is first left after passing hotel.
Follow road through to the main entrance, parking garage straight ahead.
19
<PAGE>
PROXY PROXY
ORGANOGENESIS INC.
Annual Meeting of Stockholders -- May 14, 1999
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF THE COMPANY
The undersigned, revoking all prior proxies, hereby appoint(s) Herbert M. Stein,
David T. Rovee and Donna Abelli-Lopolito and each of them, with full power of
substitution, as proxies to represent and vote, as designated hereon, all shares
of stock of Organogenesis Inc. that the undersigned would be entitled to vote if
personally present at the Annual Meeting of Stockholders to be held at The
Westin Hotel, 70 Third Avenue, Waltham, Massachusetts, on Friday, May 14, 1999
at 10:00 A.M., local time, and at any adjournment thereof.
IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER MATTERS
AS PROPERLY MAY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF.
This proxy, when properly executed, will be voted in the manner directed herein
by the undersigned stockholder(s). If no direction is given, this proxy will be
voted FOR the election of Directors and FOR Items 2 through 5. Attendance of the
undersigned at the meeting or at any adjournment thereof will not be deemed to
revoke this proxy unless the undersigned shall revoke this proxy in writing.
PLEASE FILL IN, DATE, SIGN AND MAIL THIS PROXY
IN THE ENCLOSED POST-PAID RETURN ENVELOPE
(Continued and to be signed on reverse side)
<PAGE>
Please mark your votes as in this example: [X]
UNLESS OTHERWISE INSTRUCTED, THIS PROXY WILL BE VOTED IN FAVOR OF THE ITEMS
SET FORTH BELOW.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ITEMS 1 THROUGH 5.
1. Election of Directors Nominees: Richard S. Cresse
Albert Erani
Bjorn R. Olsen, M.D., Ph.D.
Marguerite A. Piret
FOR AGAINST David T. Rovee, Ph.D.
Anton E. Schrafl, Ph.D.
[_] [_] Herbert M. Stein
FOR, except vote WITHHELD from the following nominee(s):
- ---------------------------------------------------------
2. Approve an amendment to our Restated Certificate of Incorporation, as
amended, increasing the number of authorized shares of common stock from
40,000,000 to 80,000,000 shares.
FOR AGAINST ABSTAIN
[_] [_] [_]
3. Approve amendments to our 1991 Employee Stock Purchase Plan to extend the
plan for an additional five years and to adjust the number of shares authorized
to be issued under each offering period to 30,000.
FOR AGAINST ABSTAIN
[_] [_] [_]
4. Approve an amendment to our 1995 Stock Option Plan to increase the number of
shares of common stock available for issuance pursuant to options granted under
the plan from 2,929,688 to 5,000,000.
FOR AGAINST ABSTAIN
[_] [_] [_]
5. Ratify the selection by the Board of Directors of PricewaterhouseCoopers LLP
as independent accountants for the 1999 fiscal year.
FOR AGAINST ABSTAIN
[_] [_] [_]
SIGNATURE DATE
----------------------------- ----------------------
SIGNATURE DATE
----------------------------- ----------------------
Please sign exactly as name(s) appears hereon. If the stock is registered in the
names of two or more persons, each should sign. Executors, administrators,
trustees, guardians, attorneys and corporate officers should add their titles.
